Tranexamic Acid (TXA)

Tranexamic Acid

The CRASH-2 2 (Clinical Randomisation of an Anti-fibrinolytic in Significant Haemorrhage 2) study involved the randomisation of over 20,000 patients with, or at risk of significant haemorrhage in 40 countries. The study demonstrated a 32% reduction in death due to haemorrhage, when tranexamic acid is administered within 1 h of injury. The study concluded that tranexamic acid safely reduced the risk of death in bleeding trauma patients, and should be considered for use in practice.

Following the publication of the study, the Trust has been working with Professor Stuart Logan, Director of the Peninsula National Institute of Health Research's Collaboration for Leadership in Applied Health Research and Care to implement the intervention across the South West.

For further information please contact Adrian South, Deputy Director of Clinical Care at adrian.south@swast.nhs.uk

Local Resources

Published Evidence

TXA image

Email this page Print page

News

SIGNIFICANT IMPROVEMENT TO NHS111 SERVICE IN DORSET AND CORNWALL
Responding to the Care Quality Commission’s quality report on NHS 111 services in Dorset and Cornwall, including the Isles of Scilly, published today (27 April 2017), Ken Wenman, Chief Executive, South Western Ambulance Service NHS Foundation Trust says: “We welcome this report from the CQC and in particular its acknowledgement of the significant improvements it found following a number of inspections last year.  Three of the five ratings made by the CQC are now ‘good’ and the report features many endorsements of the achievements of our NHS 111 team."  
27/04/2017

Rounded corners
Rounded corners
 
© South Western Ambulance Service NHS Foundation Trust 2017 Design by Precedent | Powered by Sitekit